-
ALSO READ
Alembic Pharmaceuticals receives EIR for its Injectable Facility at Karkhadi
Alembic Pharma's Panelav facility gets EIR from USFDA
Dr. Reddy's Lab Andhra Pradesh facility gets EIR from USFDA
USFDA issues EIR for Alembic's Panelav oncology injectable formulation unit
Jubilant Pharmova subsidiary gets EIR from USFDA
-
Alembic Pharmaceuticals rose 1.02% to Rs 507.05 after the pharma company received an Establishment Inspection Report (EIR) from the US drug regulator for the inspection carried out at its injectable facility at Karkhadi.
The US Food and Drug Administration (USFDA) conducted the pre-approval inspection from 18 August 2022 to 30 August 2022, for ANDAs filed by the company.The company said that it has already started receiving ANDA approvals manufactured at Karkhadi facility.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.
The drug maker reported 29% drop in consolidated net profit to Rs 121.92 crore despite a 18.7% rise in net sales to Rs 1509.02 crore in Q3 FY23 over Q3 FY22.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU